Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:58:20.776Z.
Consensus retrieved: 2026-10-06T15:30:37.912Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:58:20.776Z.
Quote observation: 2026-10-06T18:55:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 03323db2775440637d437753bcbe4752de1aa38160fb89fba54e51888a6c5dc1
Forward PE Ratio (N/A) = Dated Quote Price ($138.33) / Consensus Forward EPS ($4.67)
FORWARD PE RATIO
N/A
Protagonist Therapeutics, Inc.
Market Cap
$8.90B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Protagonist Therapeutics, Inc. (PTGX) | $8.90B | N/A |
| Bruker Corporation (BRKRP)vs › | $8.91B | 209.41 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.78B | N/A |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.03B | N/A |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.68B | N/A |
| Bruker Corporation (BRKR)vs › | $9.22B | 28.53 |
| Insulet Corp. (PODD)vs › | $9.38B | 20.82 |
| Oscar Health, Inc. (OSCR)vs › | $8.39B | 16.96 |
| Vaxcyte, Inc. (PCVX)vs › | $9.47B | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.62B | 42.90 |
Trailing P/E
133.8
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $4.67 implies +353.4% EPS growth vs the reported trailing $1.03.
At the dated quote price of $138.33, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $4.67 | $3.93 – $5.94 | 8 | 29.6x |
| 2027-12-31 | $-0.43 | $-17.34 – $29.42 | 8 | n/m |
| 2028-12-31 | $1.96 | $-2.73 – $7.41 | 7 | 70.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
